Since 1998, Emergent BioSolutions has been a premier source for solutions to some of the most dangerous threats to public health. Emergent is a fully integrated developer and manufacturer of biodefense & hyperimmune plasma derived products. Recent portfolio additions include infectious disease, blood disorders, oncology and biodefence targets, such as hepatitis B, botulism and anthrax. Emergent's CDMO services specialize in the custom development and manufacture of clinical/commercial drugs for pharma/biotech innovators.